HCM Stock Overview
HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in Hong Kong and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for HCM from our risk checks.
HUTCHMED (China) Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£17.36 |
| 52 Week High | UK£21.92 |
| 52 Week Low | UK£11.93 |
| Beta | 0.75 |
| 11 Month Change | -18.69% |
| 3 Month Change | 0.58% |
| 1 Year Change | -9.82% |
| 33 Year Change | -50.65% |
| 5 Year Change | -28.00% |
| Change since IPO | 28.59% |
Recent News & Updates
Recent updates
Hutchmed Growing Sales By 64% In H1 2024
Aug 09Hutchmed Is Turning Profitable
Mar 20Hutchmed begins dosing in phase 2/3 trial of sovleplenib for red blood cell disorder
Oct 10Hutchmed, Inmagene begin dosing in phase 1 trial of potential autoimmune disease drug IMG-004
Aug 09Hutchmed begins dosing in mid-stage study of tazemetostat in blood cancer subtype
Aug 01Hutchmed begins dosing in early-stage study of cancer drug HMPL-A83
Jul 15Hutchmed, Inmagene begin dosing in early-stage study of IMG-007 for eczema
Jul 06Hutchmed Roils Markets With Changing Of Its Guard, U.S. Delisting Threat
Mar 11Shareholder Returns
| HCM | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 3.7% | 1.6% | 2.2% |
| 1Y | -9.8% | 10.0% | 31.7% |
Return vs Industry: HCM underperformed the US Pharmaceuticals industry which returned 10.8% over the past year.
Return vs Market: HCM underperformed the US Market which returned 31.1% over the past year.
Price Volatility
| HCM volatility | |
|---|---|
| HCM Average Weekly Movement | 7.1% |
| Pharmaceuticals Industry Average Movement | 9.7% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: HCM has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: HCM's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 1,970 | Wei-Guo Su | www.hutch-med.com |
HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in Hong Kong and internationally. The company develops Savolitinib for the treatment of non-small cell lung cancer (NSCLC), papillary renal cell carcinoma (RCC), and gastric cancer (GC); and Fruquintinib, an inhibitor for colorectal cancer (CRC), breast cancer, gastric cancer, microsatellite stable-CRC endometrial cancer (EMC), NSCLC, RCC, gastrointestinal, cervical, and solid tumors. It also develops Surufatinib, which is used for the treatment of pancreatic neuroendocrine tumor (NET), non-pancreatic NET, neuroendocrine carcinoma, SCLC, biliary tract cancer, and solid tumors; and Sovleplenib that treats hematological cancers and certain chronic immune diseases.
HUTCHMED (China) Limited Fundamentals Summary
| HCM fundamental statistics | |
|---|---|
| Market cap | US$2.98b |
| Earnings (TTM) | -US$41.97m |
| Revenue (TTM) | US$610.81m |
4.9x
P/S Ratio-70.9x
P/E RatioIs HCM overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| HCM income statement (TTM) | |
|---|---|
| Revenue | US$610.81m |
| Cost of Revenue | US$658.26m |
| Gross Profit | -US$47.45m |
| Other Expenses | -US$5.48m |
| Earnings | -US$41.97m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.049 |
| Gross Margin | -7.77% |
| Net Profit Margin | -6.87% |
| Debt/Equity Ratio | 10.9% |
How did HCM perform over the long term?
See historical performance and comparison